P3 Health Partners Inc. reported a material improvement in profitability for the first quarter of 2026, leading to a significant stock surge [1, 2].
The results signal a potential turnaround for the Nevada-based population health management company as it attempts to stabilize its balance sheet through restructuring and debt conversion [1, 5].
The company delivered $26 million in adjusted EBITDA for the quarter [1]. This performance prompted the company to revise its full-year 2026 adjusted EBITDA outlook to a range between $20 million and $60 million [1]. Despite the adjusted gains, the company reported earnings per share of negative $1.00 [2].
Following the announcement, the company's stock surged 42.68% in after-hours trading to reach $5.75 [2]. This volatility follows a period where consensus revenue estimates for the quarter sat at $0.39 billion [3].
Executive leadership attributed the gains to a combination of clinical model refinements, and asset concentration. The company also completed a contract restructuring and a strategic debt-conversion to strengthen its financial position [5].
"Q1 represents an inflection point for the business," the P3 Health Management Team said [1].
CFO Leif Pedersen said, "We delivered $26 million of adjusted EBITDA in the quarter" [1].
CEO Aric Coffman expressed confidence in the company's current trajectory. "The economic framework for 2026 is solid within the business," Coffman said [4].
“Q1 represents an inflection point for the business.”
The divergence between the company's negative earnings per share and its positive adjusted EBITDA suggests that while P3 Health is improving its core operational efficiency, it is still grappling with significant bottom-line losses. The stock's aggressive reaction indicates investor confidence in the company's restructuring efforts and its ability to move toward sustainable profitability in the 2026 fiscal year.
